SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors focus on the company's progress with ivonescimab, specifically highlighting its potential as a disruptor in the lung cancer treatment landscape ahead of its upcoming PDUFA date. The community is actively debating the company's reliance on clinical data from China while closely watching for trial readouts that could influence its competitive standing against established market leaders.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending after reports surfaced that merger negotiations with Merck stalled due to valuation disagreements, cooling immediate buyout speculation. Despite the stock's pullback, the community remains intensely focused on the company's upcoming Phase 3 data and its long-term potential as a premier oncology asset with blockbuster prospects.

This has been pretty requested, so here's a short explainer of what $Staccana is:  @STACCoverflow has cooked up a Solana fork using some tech that was created, but never utilized since Solana cannot rollback or change inherent promises the chain makes. Here are the promises that Staccana chain makes:  a. Token transfers are encrypted by default b. Launches use frequent-batch auctions (MEV is not possible on this chain)  I've been coordinating with Stacc to help create a flywheel for this meme coin and the native ssSOL token. If you want early access to the chain, best rewards, and to become a part of this ecosystem you want to be invested in $Staccana.  Said flywheel is being cooked by Stacc as we speak, and the plan is to release Staccana main net on May 16th. I will be contributing the locked 4.6% supply to LPs for the flywheel.  Creator fees will be used to bootstrap the network, incentivize early users, and to add to the Stacanna treasury.  73edX6xoGY4v5y2hzuKdrUbJXLntqgmo74au1Ki1pump

Solana Fork Staccana

Staccana is generating buzz as investors track the project's upcoming mainnet launch and its focus on privacy-centric infrastructure for the Solana ecosystem. While some community members highlight the project's development and liquid staking potential as key drivers, others remain focused on recent large buy transactions and the anticipation of long-term utility.

Bitwise Hyperliquid ETF - Bitwise Hyperliquid ETF

Bitwise Hyperliquid ETF

The Bitwise Hyperliquid ETF is trending as investors capitalize on intense institutional buying pressure and anticipation surrounding new ETF developments. Community sentiment remains highly bullish, with many focused on the potential for a long-term breakout driven by the platform's unique role in modern digital asset finance.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies Inc. (PURR) is trending as traders speculate on a potential short squeeze, driven by significant institutional accumulation and its role as a proxy for the rapidly expanding Hyperliquid perpetual futures exchange. The community is actively discussing the stock's massive daily volume and the broader integration of tokenized assets into the U.S. financial system, fueling expectations of a long-term structural rally.

Bombardier, Inc. engages in the design, building, and maintenance of aircraft. It operates through the Business Aircraft and Others segments. The Business Aircraft segment is involved in selling new aircraft, pre-owned aircraft, and defense aircraft, as well as services and support including parts, smart services, service centers, training, and technical publications. The Others segment refers to the sale of components related to commercial aircraft programs. The company was founded on June 19, 1902 and is headquartered in Dorval, Canada.

Bombardier Inc. - Ordinary Shares - Class B (Sub Voting)

Bombardier Cl B Sv

Bombardier is trending as investors remain optimistic about its long-term turnaround, strong backlog growth, and robust demand for its business jet portfolio, though some community members are actively debating management's capital allocation and the potential impact of geopolitical tariffs on the company's defense and aerospace contracts.

SAP SE engages in the provision of enterprise application software and software-related services. It operates through the following segments: Applications, Technology, and Support; Qualtrics; and Services. The Applications, Technology, and Services segment includes sale of software licenses, support offerings, and cloud subscriptions. The Qualtrics segment sells experience management cloud solutions. The Services segment offers professional services, premium support services, implementation services for software products, and education services on the use of products. The company was founded by Hasso Plattner, Klaus Tschira, Claus Wellenreuther, Dietmar Hopp, and Hans-Werner Hector on April 1, 1972 and is headquartered in Walldorf, Germany.

Sap SE - ADR

SAP AG

SAP is currently trending due to active community debate surrounding the long-term software profit landscape, where investors are weighing its ERP dominance and steady cloud compounding against emerging competitors. While some community members highlight its institutional positioning and recent AI integration efforts, others are debating whether its valuation and cloud growth trajectories justify its market position relative to more aggressive AI-focused rivals.

Virgin Galactic Holdings, Inc. is an aerospace and space travel company, which engages in the provision of consumer space experience using reusable spaceflight systems. The firm is also involved in designing, developing, and manufacturing, ground and flight testing, spaceflight operation, and post-flight maintenance of spaceflight systems. The company was founded on May 5, 2017 and is headquartered in Tustin, CA.

Virgin Galactic Holdings Inc - Ordinary Shares - Class A

Virgin Galactic Holdings Inc

Virgin Galactic is experiencing significant retail-driven momentum as investors speculate on a short squeeze and draw parallels to the upcoming SpaceX IPO, leading to intense debate over the company's long-term business viability. The community remains deeply divided between those betting on an explosive run based on technical setups and others warning of a potential pump-and-dump scenario.

Index Coop is a decentralized autonomous organization (DAO) that builds structured DeFi products and strategy tokens. Index Coop offers a suite of sector index products, leverage and inverse products, and yield-generating products. The product suite runs on Set Protocol, an audited, self-custodial DeFi tool that allows for the creation and management of Ethereum-based (or ERC-20) tokens. Changes to the DAO are voted on by the owners of a governance token called INDEX and then implemented by a team of developers. INDEX holders wield voting power on a 1:1 basis, meaning one token equals one vote.

Index Cooperative

Index Cooperative is trending as community members rally behind the token, fueled by speculative hopes for a potential price surge and broader optimism regarding incoming crypto market structure legislation. Discussions are heavily focused on accumulation strategies, with many investors highlighting the project's low market cap as a catalyst for a possible significant move.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending as investors debate whether the token is at a critical floor or nearing further downside, with the community split between bearish "suckers" narrative and speculative interest in real-world asset tokenization. The conversation is dominated by intense skepticism regarding long-term growth and a high-stakes sentiment battle over whether the current price action signals a recovery or a continuation of a long-term downtrend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates

Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +5.96% and +102.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of +39.00% and +2.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Upstream Bio (UPB) to Release Quarterly Earnings on Tuesday

Upstream Bio (NASDAQ:UPB) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...

Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) has been given an average rating of "Moderate Buy" by the five analysts that are covering the company, MarketBeat.com reports. One research analyst...

Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two h...

Upstream Bio (NASDAQ:UPB) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen lowered shares of Upstream Bio from a "hold" rating to a "sell" rating in a research note on Saturday...

Upstream Bio (NASDAQ:UPB) Downgraded by Evercore to In-Line

Evercore downgraded shares of Upstream Bio from an "outperform" rating to an "in-line" rating and set a $15.00 target price on the stock. in a research note on Friday...

Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data

Upstream Bio outlines Phase 3 plans for verekitug as asthma and CRSwNP data support dosing strategy; shares rise on update.read more...

Upstream Bio (NASDAQ:UPB) Posts Earnings Results, Misses Estimates By $0.06 EPS

Upstream Bio (NASDAQ:UPB - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.06). The company had revenue of $0.67 million for the quarter, compared to analyst...

Upstream Bio (NASDAQ:UPB) Trading Up 11.2% - What's Next?

Upstream Bio (NASDAQ:UPB) Stock Price Up 11.2% - Here's Why...

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in April 2021 and is headquartered in Waltham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.74	--	--	N/A
Q1 '26	-$0.73	--	--	N/A
Q4 '25	-$0.75	--	--	N/A
Q3 '25	-$0.68	-$0.63	7.62%	BEAT
Q2 '25	-$0.74	-$0.74	--	EXPECTED

UPB
Upstream Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings

Compact View

Latest UPB News

UPBUpstream Bio Inc.